论文信息 - 1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY - 字舞流文

1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY

Masatoshi Kudo | Yoon-Koo Kang | Won Young Tak | Rana Ezzeddine | M. Kudo | J. Bruix | M. Sherman | J. Llovet | R. Finn | Yoon-Koo Kang | Joong-Won Park | E. Assenat | Y. Chao | R. Poon | V. Boige | T. Decaens | H. Lim | J. Blanc | J. Raoul | W. Tak | D. Lin | P. Mathurin | L. Fartoux | Richard S. Finn | Jordi Bruix | Morris Sherman | Valérie Boige | Yee Chao | Jean-Frédéric Blanc | Philippe Mathurin | Charissa Y. Chang | R. Ezzeddine | Laetitia Fartoux | Josep M. Llovet | Thomas Decaens | J.-L. Raoul | Eveline Boucher | Eric Assenat | Ho Yeong Lim | Deng-Yn Lin | Ronnie T.P. Poon | David Liu | Ian Walters | Joong Won Park | E. Boucher | I. Walters | David Liu